Aclarion Provides 2025 Update and 2026 Corporate Outlook
Rhea-AI Summary
Aclarion (Nasdaq: ACON / ACONW) provided a 2026 corporate outlook and 2025 operational update centered on its Nociscan platform for chronic low back pain. Key metrics: 2025 annual scan volumes +69% YoY, Q4 2025 volumes +114% YoY. The company reported a debt-free balance sheet with $12.0 million cash as of Dec 31, 2025, following >$22.0 million equity raised in 2025, and expects cash to fund operations into H1 2027. Clinical progress includes the CLARITY trial (7 activated sites) with a goal to enroll ~25% of patients by end of Q2 2026 and an initial internal 3-month readout anticipated in Q3 2026. Additional 2025 milestones: 9 new imaging centers, 22 new physician users, and 4 issued patents.
Positive
- Scan volumes +69% year-over-year in 2025
- Q4 2025 scan volumes +114% year-over-year
- Debt-free with $12.0M cash as of 12/31/2025
- Raised >$22.0M in equity financing during 2025
- Goal to have ~25% of CLARITY patients enrolled by end of Q2 2026 with internal readout in Q3 2026
Negative
- Cash runway limited to operations into H1 2027 based on current plans
- Commercial program still described as early-stage despite volume growth
News Market Reaction 47 Alerts
On the day this news was published, ACON gained 42.09%, reflecting a significant positive market reaction. Argus tracked a peak move of +41.4% during that session. Argus tracked a trough of -28.2% from its starting point during tracking. Our momentum scanner triggered 47 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $2M to the company's valuation, bringing the market cap to $5M at that time. Trading volume was exceptionally heavy at 404.7x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
ACON gained 7.08% while peers were mixed: BFRG up 5.33%, DRIO down 8.25%, WORX and VSEE slightly negative, POAI flat. This points to a stock-specific reaction rather than a sector-wide move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 06 | CLARITY trial update | Positive | +3.7% | Expanded CLARITY sites and guidance on interim data and enrollment goals. |
| Dec 04 | Clinical publication | Positive | +5.0% | Featured Nociscan article showcasing case study and noninvasive SaaS platform. |
| Dec 02 | Commercial hire | Positive | +10.3% | Appointment of Eastern U.S. Commercial Director to drive Nociscan adoption. |
| Nov 05 | UK commercial expansion | Positive | +0.0% | New UK Commercial Director and reimbursement by major UK private insurers. |
| Oct 22 | Industry award | Positive | -4.7% | Digital Health “Rising Star” award recognizing Nociscan platform capabilities. |
Recent company news, particularly around Nociscan validation, commercialization, and CLARITY trial progress, has generally coincided with positive or stable price reactions, with only one notable divergence.
Over the last few months, Aclarion has focused on expanding Nociscan’s clinical and commercial footprint. On Oct 22, 2025 it received a “Rising Star” digital health award tied to Nociscan. Subsequent releases in Nov–Dec 2025 highlighted UK reimbursement, commercial hires, and a featured Nociscan article in IJSS, all with mostly positive price reactions. The Jan 6, 2026 CLARITY enrollment update reinforced trial progress. Today’s corporate/financial update builds directly on those themes of evidence generation, market access, and balance-sheet strengthening.
Market Pulse Summary
The stock surged +42.1% in the session following this news. A strong positive reaction aligns with the company’s solid operational and financial update. Investors received confirmation of 114% Q4 2025 scan growth, a debt-free balance sheet with $12.0 million in cash, and over $22.0 million raised in 2025, supporting a runway into 2027. Historical news flow has often seen aligned positive moves, though low float and prior financings mean sentiment could shift quickly if expectations change.
Key Terms
mr spectroscopy medical
real-world evidence medical
cme events medical
AI-generated analysis. Not financial advice.
- Quarterly Nociscan scan volumes increased
114% year-over-year in Q4 2025 - Annual Nociscan scan volumes increased
69% year-over-year in 2025 - Debt-free balance sheet with
$12.0 million in cash as of December 31, 2025, extending cash runway into 2027 and providing strategic flexibility for continued commercial growth - Company aims to enroll approximately
25% of patients in CLARITY trial by the end of Q2 2026, with the first internal readout on interim data anticipated in Q3 2026
BROOMFIELD, Colo., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain today provided a comprehensive corporate update, including financial results and strategic progress as the Company enters 2026 advancing its proprietary Nociscan platform.
Market Adoption & Growth Momentum
During 2025, Aclarion continued to build on its mission to transform the diagnosis of chronic low back pain achieving
- Nociscan scan volumes increased +
114% year-over-year in Q4 2025 – marking the third consecutive quarter of year-over-year growth across U.S., UK, and E.U. sites. - Aclarion remains focused on expanding its commercial presence within key UK and U.S. healthcare markets. Efforts during the period included:
- The addition of 9 new imaging centers in 2025
- The addition of 22 new physician users in 2025
- Expansion of team with key leadership and commercial hires in the U.S. and UK
Strategic and Operational Highlights
- Continued advancement of Nociscan platform, with progress across clinical validation, commercial readiness, and customer engagement initiatives.
- Strengthened clinical evidence base, including ongoing and planned studies supporting the clinical and economic value of Nociscan.
- Expanded engagement with healthcare providers and payors, aimed at improving adoption and reimbursement pathways.
- Disciplined capital management, focused on extending operational runway while prioritizing value-creating milestones.
- Ongoing evaluation of strategic partnerships and growth opportunities to accelerate commercialization and market penetration.
- Bolstered intellectual property footprint with 4 new issued patents in 2025, with a total of 52 issued patents worldwide covering Aclarion's core technology and specific applications.
Clinical and Product Developments
- Launching the CLARITY trial in 2025 at 7 activated sites illustrates Aclarion’s ongoing commitment to leading with evidence and lays the groundwork for future commercial expansion.
- 2025 publications of real-world evidence demonstrate clinical utility and economic value.
- Cost-effectiveness analysis published in ClincoEconomics and Outcomes Research in April. The analysis concluded that Nociscan is more effective and less costly than provocative discography, illustrating that Nociscan saves
$1,712 per patient and improves surgical success rates by10% . - MR Spectroscopy and Low Back Pain: A Novel Cloud-based Solution, Nociscan published in Special Pain Issue of the International Journal of Spine Surgery (IJSS) in December. The featured article included a technology overview of Nociscan and highlighted a successful case study.
- Cost-effectiveness analysis published in ClincoEconomics and Outcomes Research in April. The analysis concluded that Nociscan is more effective and less costly than provocative discography, illustrating that Nociscan saves
In 2026, the Company expects to:
- Advance clinical validation efforts:
- Accelerate enrollment with goal of enrolling approximately
25% of patients in the CLARITY trial by the end of Q2 2026. An initial readout will be internally available after the initial cohort of patients complete their 3-month follow up visit. - Complete and publish multiple investigator-initiated real world evidence trials.
- Expand major MRI manufacturer access growing the available global market size by greater than
30% .
- Accelerate enrollment with goal of enrolling approximately
- Support broader clinician education and awareness initiatives through accelerated participation at societal-sponsored CME events.
- Continue refining workflow integration to support scalability in clinical practice by launching version 2.8 of our Nociscan software in Q1.
- Actively collaborate with multiple commercial payers in the US market to evaluate broad reimbursement coverage of Nociscan.
Financial Highlights
As of December 31, 2025, the Company had
There were 854,371 common shares and 28,000 prefunded warrants outstanding as of December 31, 2025. On a fully diluted basis, this represents approximately
Based on current operating plans, the Company believes its existing cash resources are sufficient to fund operations into the first half of 2027.
Management Commentary
“We are pleased with the progress Aclarion has made in strengthening our financial position, expanding clinical traction, and advancing Nociscan toward broader adoption,” said Brent Ness, CEO of Aclarion.
“Despite the early-stage nature of our commercial activities, the growth in scan volume particularly in the UK where we enjoy commercial payer reimbursement, and meaningful capital raises during 2025, reflect both momentum and investor confidence. We remain focused on execution through leadership team investments, evidence generation, and strategic partnerships to drive long-term value for patients, providers, payers and shareholders.”
About Aclarion, Inc.
Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit www.aclarion.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company’s current plans and expectations, as well as future results of operations and financial condition. Forward-looking statements in this release include, among others, statements regarding the enrollment of patients in our ongoing clinical trial, the expected date of the internal interim results, the potential benefits of our Nociscan technology, and the Company’s plans for future regulatory and commercialization activities, as well as the cash need to fund operating into 2027. These and other risks and uncertainties are discussed more fully in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, as well as other disclosures contained in the Prospectus and subsequent filings made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Contacts:
Kirin M. Smith
PCG Advisory, Inc.
ksmith@pcgadvisory.com
Media Contacts:
Jessica Starman
media@elev8newmedia.com
FAQ
How much cash did Aclarion (ACON) have at December 31, 2025 and how long will it fund operations?
What were Aclarion's Nociscan scan volume growth rates in 2025 and Q4 2025 (ACON)?
What is the CLARITY trial enrollment target and timing for Aclarion (ACON)?
How much equity financing did Aclarion (ACON) raise in 2025 and what was the impact on liquidity?
What commercial expansion did Aclarion (ACON) report for 2025?
